primary antibodies against α tubulin  (Proteintech)

Journal: PLOS One

Article Title: Enarodustat suppresses thymic stromal lymphopoietin expression via hypoxia-inducible factor-mediated c-Jun N-terminal kinases dephosphorylation

doi: 10.1371/journal.pone.0341552

Figure Lengend Snippet: (A) Expression levels of phospho-JNK after SP600125 and FSL-1 treatment. Samples were collected 30 min after FSL-1 stimulation. Phospho-JNK and α-tubulin proteins were determined by western blotting. α-tubulin was used as a loading control. (B) Effects of SP600125 on FSL-1 induced TSLP mRNA expression. (C and D) Effects of T-5224 on TSLP mRNA expression levels induced by TNF-α (C) or PAR2-agonist + IL-4 (D). (E) The effects of SP600125 on TSLP mRNA expression induced by PAR2-agonist + IL-4. * p < 0.05, ** p < 0.01 vs. stimulation alone group. Data are represented as the mean ± S.E.M. ( n = 3-4). N.S.; not significant.

Article Snippet: Primary antibody against α-tubulin was purchased from Santa Cruz Biotechnology (Texas, USA).

Techniques: Expressing, Western Blot, Control

Journal: PLOS One

Article Title: Enarodustat suppresses thymic stromal lymphopoietin expression via hypoxia-inducible factor-mediated c-Jun N-terminal kinases dephosphorylation

doi: 10.1371/journal.pone.0341552

Figure Lengend Snippet: (A) Expression levels of IκBα after enarodustat and FSL-1 treatment. Samples were collected 30 min after FSL-1 stimulation. IκBα and α-tubulin proteins levels were determined by western blotting. α-tubulin was used as a loading control. (B) Expression NF-κB p65 in nuclear fraction. Histone H3 was used as a loading control for the nuclear fraction samples. α-tubulin was used as a loading control for the total cell lysate. (C) Concentration-dependent effects of TPCA-1 on TSLP mRNA expression in FSL-1-stimulated HaCaT cells. (D) Effects of enarodustat on TSLP mRNA expression after TPCA-1 treatment. * p < 0.05, ** p < 0.01 vs. FSL-1 alone group. Data are represented as the mean ± S.E.M. ( n = 3). N.S., not significant.

Article Snippet: Primary antibody against α-tubulin was purchased from Santa Cruz Biotechnology (Texas, USA).

Techniques: Expressing, Western Blot, Control, Concentration Assay

Journal: PLOS One

Article Title: Enarodustat suppresses thymic stromal lymphopoietin expression via hypoxia-inducible factor-mediated c-Jun N-terminal kinases dephosphorylation

doi: 10.1371/journal.pone.0341552

Figure Lengend Snippet: HaCaT cells were transfected with siRNAs at the time of seeding. Cells were treated with enarodustat 24 h before FSL-1 stimulation. (A and B) mRNA expression levels of HIF1α (A) and HIF2α (B) 72 h after siRNA transfection. * p < 0.05, ** p < 0.01 vs. control siRNA-treated group. Data are represented as the mean ± S.E.M. ( n = 3). (C) Protein expression levels of HIF1α in enarodustat- and FSL-1-treated groups after control or HIF siRNA treatment. (D) Intensity ratio of HIF1α/α-tubulin in enarodustat treated groups under control siRNA or HIF siRNA treated condition. Band intensity was quantified using the ImageJ software. (E) TSLP mRNA expression levels in control- and HIF siRNA-treated cells. * p < 0.05, ** p < 0.01 vs. FSL-1 alone group. Data are represented as the mean ± S.E.M. ( n = 3). N.S.; not significant.

Article Snippet: Primary antibody against α-tubulin was purchased from Santa Cruz Biotechnology (Texas, USA).

Techniques: Transfection, Expressing, Control, Software

Journal: International Journal of Medical Sciences

Article Title: Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation

doi: 10.7150/ijms.119034

Figure Lengend Snippet: Overexpression of PSMA6 correlated with tumor malignancy of BLCA. (A-D) The association of the PSMA6 mRNA expression with tumor grade. (E-H) The association of the PSMA6 mRNA expression with pathological T stage. (I, J) Representative IHC images of the PSMA6 protein expression in indifferent pathological grade and stage. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Primary antibodies against PSMA6 (1:1000, 11573-1-AP, Proteintech) and Tubulin (1:1000, 11224-1-AP, Proteintech) were applied.

Techniques: Over Expression, Expressing

Journal: International Journal of Medical Sciences

Article Title: Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation

doi: 10.7150/ijms.119034

Figure Lengend Snippet: PSMA6 was highly expressed in BLCA. (A-C) Boxplots of PSMA6 relative expression based on cancer stage, lymph node metastasis and patient's smoking habit. (D) PSMA6 mRNA expression in five BLCA subtypes. (E) PSMA6 protein level in 20 paired BLCA tissues (T) and their adjacent normal urothelium tissues (N). (G) Representative IHC images of PSMA6 expression in noncancerous and BLCA tissues. Scale bar, 100 and 20 μm. **P < 0.01; ***P < 0.001.

Article Snippet: Primary antibodies against PSMA6 (1:1000, 11573-1-AP, Proteintech) and Tubulin (1:1000, 11224-1-AP, Proteintech) were applied.

Techniques: Expressing

Journal: International Journal of Medical Sciences

Article Title: Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation

doi: 10.7150/ijms.119034

Figure Lengend Snippet: Gene function enrichment analysis between PSMA6 high and low subgroups. (A) Heatmap of DEGs between PSMA6 high-expression and low-expression groups. (B) GO enrichment analysis of DEGs. (C) KEGG enrichment analysis of DEGs. (D) GSEA results showing the top eight significant pathways.

Article Snippet: Primary antibodies against PSMA6 (1:1000, 11573-1-AP, Proteintech) and Tubulin (1:1000, 11224-1-AP, Proteintech) were applied.

Techniques: Expressing

Journal: International Journal of Medical Sciences

Article Title: Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation

doi: 10.7150/ijms.119034

Figure Lengend Snippet: PSMA6 was involved in tumor immunity in BLCA. (A) Difference in the proportions of immune cell type in BLCA with low or high PSMA6 expression. (B) The association of PSMA6 expression with immune cell types and immune-related functions. (C) The correlation of PSMA6 expression with TICs. (D) The correlation of PSMA6 expression with immune checkpoint blocker. (E) The correlation of PSMA6 expression with IPS. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Primary antibodies against PSMA6 (1:1000, 11573-1-AP, Proteintech) and Tubulin (1:1000, 11224-1-AP, Proteintech) were applied.

Techniques: Expressing

Journal: International Journal of Medical Sciences

Article Title: Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation

doi: 10.7150/ijms.119034

Figure Lengend Snippet: Knockdown of PSMA6 suppressed BLCA cell proliferation in vitro . (A) PSMA6 protein levels in multiple BLCA cell lines measured by western blotting. (B, C) Interference efficiency of two specific shRNAs (sh1 and sh2) to PSMA6 in BLCA cells was measured by qRT-PCR and western blotting. (D-G) Effects of PSMA6 knockdown on cell viability and colony formation. (H, I) Effects of PSMA6 knockdown on cell proliferation were determined by EdU. Scale bar, 200μm. (J, K) Effects of PSMA6 knockdown on cell cycle were determined by flow cytometry analysis. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Primary antibodies against PSMA6 (1:1000, 11573-1-AP, Proteintech) and Tubulin (1:1000, 11224-1-AP, Proteintech) were applied.

Techniques: Knockdown, In Vitro, Western Blot, Quantitative RT-PCR, Flow Cytometry

Journal: International Journal of Medical Sciences

Article Title: Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation

doi: 10.7150/ijms.119034

Figure Lengend Snippet: Silencing of PSMA6 inhibited BLCA cell growth in vivo . (A) Images of Xenografts from negative control (shNC) and PSMA6 silenced (sh2) groups (n = 6). (B) Tumor volume growth curves. (C) Average xenograft tumor weights. (D) Representative IHC images of PSMA6 and Ki67 protein expression in xenograft tumors. Scale bar, 100 and 20 μm. **P < 0.01; ***P < 0.001.

Article Snippet: Primary antibodies against PSMA6 (1:1000, 11573-1-AP, Proteintech) and Tubulin (1:1000, 11224-1-AP, Proteintech) were applied.

Techniques: In Vivo, Negative Control, Expressing